OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

must have been asleep, didn't notice this increase! What fantastic news!!! should be over a 1 soon as it was in yr2000 it got to 135p nearly ten yrs ago, the Bio Sector is well and truly undervalued at present and with this news which I was hoping for early next yr, should seriously re-rate the sp.

Woaha there, whilst this is good-news it is only PhI/II - and there are plenty of failures in PhIII trials (DYOR).

Still as a bit of good-news this is most welcome, esp. as I'm nearing "evens" at about 30p - so not too far to go, bearing in mind that investors are holding onto their wallets until there is a general "feel-good" about.

However, I can't see robstuff's "...soon over1..." on the basis of this little comment.....but there may be more - this not a 1-product company AND they have plenty of Cash, after the shuffle at partners Sanoffi.

A great day todaybut I feel we need several days to get a handle on sp two companies in the last two days reported good news about PD in Phase 1 trialspeople are bound to make comparisons with pymit has been said by oxb on the August web cast/conference call re Prosavin deal JD said they were at an advanced stage of the discussions and later when pressed said that they were more advanced with one suitor than with another.it is believed oxb had the Prosavin data over a fortnight ago and could have been playing one potential partner against another in the hopes of a combined announcementmaybe?the company has been a lot higher with a lot less meat on the boneinteresting stagea nice glass beckonstoddle pip.

Guardian : " More potentially good news for sufferers of Parkinson's disease. After yesterday's announcement of successful studies for Phytopharm's Cogane treatment, comes a positive update from Oxford BioMedica.

The gene therapy company said new Phase 2 data showed patients showed improvement after receiving a second dose of its ProSavin treatment. The company said after this six month assessment there was now the opportunity to try a higher dose which could be even more effective. Meanwhile a research paper on ProSavin published yesterday in the Science Translational Medicine journal also suggested positive results from the treatment.

Much like Phytopharm yesterday, the news has lifted Oxford's shares and they are now 9p higher at 19.75p. KBC Peel Hunt issued a buy note with a 17p price target (since overtaken by the market's enthusiasm) and said:

This [data] puts the product in line with the leading gene therapy treatments in development. The therapy is potentially complementary to oral products such as Phytopharm's Cogane.

We expect a higher dose of Prosavin to be trialled shortly, with a larger number of patients before the start of Phase II/III trials. Focus is now on securing commercial partners for [cancer vaccine] Trovax and Prosavin, and time lines are uncertain."

Having read the PYM statements and OXBs OXB seems more of a breakthrough and could be used in collaborations making it very marketable and a partner agreement is likely to be announced shortly.

Wide press coverage overnght should push sp higher at the opening Fri am

Sadly the reverse is true so far !!

Oakapples142.I dont like to predict SPs but with Prosavin Hi-8Mel and Trovax deals imminentI know who wants the stock most

expect some large hdgs to be announced soon

Bingo...
RNS Number : 0232B
Oxford Biomedica PLC
19 October 2009

Barclays Global Investors Ltd
Barclays Stockbrokers Ltd
Gerrard Investment Management Ltd


Threshold(s)that is/are crossed or 6% to 7%

there's one, they didn't time it perfectly but increasing to 7% very good sign and must be confident, have we bottomed out on the profit taking? onwards upwards we hope now.

I expected this drop over the coming days as most traders are impatient and edgyas an investor I thank those traders for highlighting oxb achievementsheadline newsthey have unfortunately done their nuts from the 21p trading highand punting blind...the final few are excepting their loss as they need a stakeI would suggest others research this companyparticularly from around May.

Encouraging broker note yesterday..

ASTAIRE & CO


Subject: Oxford BioMedica (OXB.L) Moving on from a challenging year - Recommendation: BUY

Please find attached my note on Oxford BioMedica Moving on from a challenging year

Oxford BioMedica has overcome major challenges since it announced in July 2008 that its most advanced product, TroVax, was going to fail its Phase III trial. ProSavin is delivering impressive clinical results and recent data show that TroVax still has a promising commercial future. The companys financial position is sufficiently strong to allow maximisation of the value of these assets. We maintain our BUY recommendation and target price of 25p.

Valuation: The company is valued at 25p, with a market cap of 135m based on a risk-adjusted SOTP valuation, representing 85% upside, and this will increase as its products pass development milestones.

Newsflow: There is the prospect of ProSavin being out-licensed and TroVax re-starting clinical development in the coming months, both of which should cause the shares to appreciate significantly in value.

TroVax, the therapeutic cancer vaccine: The latest data from the TRIST trial indicate that the drug still has a significant commercial future, and we forecast it will generate total sales of 630m. We anticipate that TroVax will resume clinical development with the support of a clinical research organisation.

ProSavin, the Parkinsons Disease treatment: ProSavin has demonstrated in preclinical studies that it can effectively cure Parkinsons Disease, and initial data from its Phase I/II trial is confirming its potential. We believe that the product will gain further validation in the coming months from an out-licensing agreement and will go on to generate total sales of 680m.

Financial strength: The company strengthened its balance sheet with the receipt of US$26m after entering a development and commercialisation collaboration with Sanofi-Aventis and had cash reserves of 34.8m at end June 2009. It now has sufficient capital to operate into H1 2012 without any further cash inflows and we anticipate that these will increase further with licensing deals and asset sales.

Not sure I accept the findings of Astaire, they were another name that found it necessary to w*p* th* sl*t* (DYOR), can't recall their name; but maybe someone here does....

OXB is bound to fluctuate as "traders" make their money, but the hope is this stock will rise on Merit, over the next few months, but it could take a lot longer, so that itself means that any Broker comments are unlikely to refelect the L-T reality, er IMHO. I Hold.

i just came across a curiosity dated 10/10/07 .... they were assuredly stocks that someone had rated strongly for the the coming year

OXB ...... mid price then 35.75 ....... close of biz today 14.25

VIY ...... mid price then 9.25 ....... close of biz today 4.85
AZM ...... mid price then 80.0 ....... close of biz today NIL (bankrupt)
BLZ ...... mid price then 67.25 ....... close of biz today 48.0
BVC ...... mid price then 31.0 ....... close of biz today 52.5


good innit!
the only winner is BVC, which to give MRSI his due, he has always promoted.
The others are shit and worse!

Oxford Biomedica Interim Management Statement



TIDMOXB

RNS Number : 7413C
Oxford Biomedica PLC
19 November 2009

?








+---------------------------------------------------+--------------------------+
| | |
+---------------------------------------------------+--------------------------+
| For Immediate Release | 19 NOVEMBER 2009 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA PLC
INTERIM MANAGEMET STATEMENT


Oxford, UK - 19 November 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, today publishes its interim management statement for the period
from 1 July to 18 November 2009.


Highlights
* TroVax : clinical and regulatory support for further trials in several cancer
settings
* ProSavin : modified administration has potential to enhance and accelerate
development
* Ocular programmes: on track to start clinical trials in 2010 with sanofi-aventis
* Financial review: cash burn in line with budget



TroVax (cancer): clinical and regulatory support for trials in several cancer
settings
Interim results from the Phase III TRIST study of TroVax in renal cancer were
presented at the joint congress of the European Cancer Organisation and the
European Society for Medical Oncology in September. As previously reported, the
TRIST study did not achieve its primary endpoint of an improvement in survival.
However, the results confirmed the findings from previous trials, demonstrating
that the anti-5T4 immune response induced by TroVax is associated with enhanced
survival. Encouragingly, TroVax showed statistically significant survival
benefit in one of the pre-defined patient subsets.


Exploratory analyses of the TRIST data identified a relationship between
patients' blood cell counts and TroVax-related survival benefit. In patients
with aberrant levels of certain blood cells at the start of the study, TroVax
appeared to be less beneficial. Excluding these patients, there was a promising
survival trend in favour of TroVax versus placebo. In this patient group, which
represented more than 50% of the TRIST population, the indicative efficacy of
TroVax was consistent with the level required to meet the study's primary
endpoint. In future trials, the ability to select patients who are more likely
to mount stronger anti-5T4 immune responses and benefit from TroVax potentially
increases the predictability of clinical outcome and the likelihood of
successful development.


The competitive landscape for the treatment of renal cancer is considerably more
crowded today than when the TRIST study was initiated in 2006. As a result,
other cancer settings may offer a more attractive initial route to market for
TroVax. The TRIST results have been discussed with the US Food and Drug
Administration (FDA). Several settings for possible further development were
presented to the FDA. These included ovarian cancer, hormone-refractory prostate
cancer and triple-negative breast cancer, which have clear unmet needs and a
lack of effective treatments. The agency was supportive of these proposed
indications for trials of TroVax. Based on our extensive Phase II data, the FDA
also invited submissions for Phase II or adaptive Phase II/III trials in
metastatic colorectal cancer.


Following the outcome of the FDA's review in July, we embarked on an initiative
to re-partner TroVax. Based on preliminary feedback, prospective partners are
attracted by the potential to select patients that are more likely to benefit
from TroVax. There remains strong support from clinicians for conducting further
trials in our targeted settings and we are exploring funding
options through clinical networks. Partnering TroVax for Phase III
development remains a key strategic priority for Oxford BioMedica, and
discussions are ongoing. Prior to securing a partner, we would only consider
supporting cost-effective Phase II trials that are designed to demonstrate proof
of concept at the earliest opportunity.


ProSavin (Parkinson's disease): potential to enhance and accelerate development
We reported further encouraging data from the Phase I/II dose-escalation study
of ProSavin in October. Patients at the second dose level showed greater
improvement in motor function at their six-month assessments compared to three
months. The maximum improvement was 53% and the average was 34% relative to
baseline. If confirmed in placebo-controlled studies, ProSavin would represent a
significant advance to current treatment options, given its potential to enhance
patients' quality of life and suppress the complications caused by oral L-DOPA
therapy.


The excellent safety profile and promising efficacy of ProSavin at the first and
second dose levels justify further escalation of the dose. The French regulatory
agency (AFSSAPS) is evaluating our proposal to escalate to the allometric human
equivalent of the highly efficacious preclinical dose level. In addition, we are
seeking to modify the administration procedure using an injection technique that
requires fewer needle tracks and reduces the surgery time. Both the study's Data
Monitoring Committee and the Company's Scientific Advisory Board support this
strategy. Enhancing the efficacy of ProSavin and reducing the surgery time could
accelerate the overall development timelines and expand the market opportunity.
We anticipate guidance on our proposed amendment from the AFSSAPS before the end
of 2009.


The ground-breaking preclinical results were published in the 14 October issue
of Science Translational Medicine, a leading scientific journal. The paper
described several proof-of-concept studies in the industry-standard preclinical
model of severe Parkinson's disease. In this model, ProSavin significantly
increased dopamine production from 27% to 47% of normal concentrations without
the addition and side-effects of standard L-DOPA therapy. The timing of the
publication supports our initiative to raise the profile of ProSavin in other
territories and to engage with the European regulatory agency (EMEA) and the
FDA.


As we advance to larger trials, we are negotiating with prospective partners
who could add value through their expertise in Parkinson's disease and could
bring additional resources for the next stage of development. Our collaboration
strategy is to retain certain territorial rights to establish our own specialist
sales force for commercialisation of ProSavin.


Ocular programmes: on track to start clinical trials in 2010 with sanofi-aventis
Our collaboration with sanofi-aventis, signed in April, supports the development
of our four LentiVector -based product candidates for ocular diseases. In
addition to the upfront payment received, sanofi-aventis has committed up to
US$24 million over a three-year period to reimburse our development costs. All
four programmes are progressing towards clinical development in 2010-11.


The most advanced candidate is RetinoStat for wet age-related macular
degeneration. We have had a constructive dialogue with the FDA regarding the
planned Investigational New Drug (IND) application. The requirements for the IND
have been agreed with the agency and we are on track to complete the
non-clinical package and submit our IND application in the second half of 2010.


Our second candidate, StarGen(TM) for Stargardt disease, is also expected to
enter clinical development before the end of 2010. We aim to conduct the Phase
I/II trial in France with Professor JosAlain Sahel, Head of the Ophthalmology
Department at the Quinze-Vingts Hospital in Paris. Preparations are ongoing and
we plan to engage the AFSSAPS within the next few months for formal guidance on
our Clinical Trial Application.


Financial review: cash burn in line with budget
In our interim results, we reported that our net cash1 balance at 30 June 2009
of GBP34.8 million was sufficient to support our operations into 2012.
Expenditure and net cash outflow in the subsequent period to 18 November have
been in line with this budget. We continue to review our development priorities
against our goals of maximising value and minimising risk through
collaborations. We expect to report a net cash inflow for the current year
following the significant cash receipts from sanofi-aventis in the first half of
2009 relating to our ocular collaboration and the return of rights to TroVax.


Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "We have
made real progress during the period in both our development and commercial
activities. The Phase I/II study of ProSavin continues to yield encouraging data
and we are excited by the potential for further enhancement at the next dose
level. TroVax is attracting increasing interest and we are working with leading
clinicians who have expressed interest in conducting further trials. Our ocular
collaboration with sanofi-aventis is on track and the first two products are
expected to enter the clinic in 2010. Our partnering efforts are focused on
ProSavin and TroVax and we are pursuing other opportunities to accelerate the
transformation of Oxford BioMedica into a sustainable biopharmaceutical
company. Looking back over my first year as Chief Executive, I am pleased to
reflect on our achievements and I look forward to building on this progress."

RNS Number : 1072E
Oxford Biomedica PLC
14 December 2009

?








+---------------------------------------------------+--------------------------+
| | 2009/OB/23 |
+---------------------------------------------------+--------------------------+
| EMBARGOED UNTIL 7.00AM, 15 DECEMBER 2009 | 15 DECEMBER 2009 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA'S STARGEN(TM) FOR STARGARDT DISEASE RECEIVES EUROPEAN ORPHAN
DRUG DESIGNATION


Oxford, UK - 15 December 2009: Oxford BioMedica (LSE: OXB), a leading gene
therapy company,
announced today that StarGen, the Company's gene-based
therapy for Stargardt disease, has received orphan designation from the
Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA).
Stargardt disease is a hereditary disorder of the eye that is caused by
abnormalities in a gene called ABCA4 in the retina. StarGen is designed to
deliver a corrected version of the ABCA4 gene into the cells of the retina using
the Company's LentiVector technology. In collaboration with sanofi-aventis,
clinical development is expected to start in 2010. The US charity, Foundation
Fighting Blindness, is also supporting the programme and previously funded the
preclinical development.


The EMEA grants orphan drug designation to products that may provide a
significant advantage over current treatments, if any
exist, for life-threatening or chronically debilitating conditions affecting up
to five in 10,000 people in the European Union. Companies with European orphan
drug designation benefit from incentives, including ten years of marketing
exclusivity and reduced regulatory fees.


Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "There is a
real and urgent need
for an effective treatment of Stargardt disease. Gene
correction offers the only means of addressing the root cause of this
debilitating, sight-robbing disorder. The EMEA's decision to grant orphan
designation to StarGen adds significant value by providing development,
regulatory and commercial advantages. StarGen is one of the four gene-based
therapies for ocular diseases that we are developing in collaboration with
sanofi-aventis and it also benefits from the Foundation Fighting Blindness'
valuable assistance. Both StarGen and our other lead ocular programme,
RetinoStat for wet age-related macular degeneration, are on track to enter
clinical development in 2010."
-Ends-

Oxford strengthen the Board and Management team..






RNS Number : 0095F
Oxford Biomedica PLC
05 January 2010






OXFORD BIOMEDICA PLC
MANAGEMENT AND BOARD CHANGES


Oxford, UK - 5 January 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, today announces the appointments of Dr Paul Blake and Dr Andrew Heath
as independent Non-Executive Directors, and the retirement from the Board of
Mark Berninger. These changes became effective on 1 January 2010. In addition,
the management team was strengthened by the appointment in November 2009 of Dr
Adam Love as Senior Director, Commercial Activities and Strategic Planning.

........................

SADIF Analytics releases new summary due diligence report for Oxford BioMedica plc
2010-01-13 12:37:19 - SADIF-Investment Analytics has applied its StockMarks stock-rating system to Oxford BioMedica plc and produced a report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal 13/01/2010 SADIF Investment Analytics, announces a new summary due diligence report covering Oxford BioMedica plc (OXB). The report uses SADIF's powerful StockMarks stock rating system and contains important analysis for any current or potential Oxford BioMedica plc investor.

Report Summary: Oxford BioMedica plc is an above average quality company with a neutral outlook. Oxford BioMedica plc has strong business growth and is run by passable management. When compared to its closest peer, Vectura Group PLC, Oxford BioMedica plc shows greater overvaluation and is more likely to outperform the market.

The 8-page report breaks down the Total StockMark into its three components business, management and price, performing an in-depth analysis of Oxford BioMedica plc for long-term investors.

The report has been distributed to Reuters, and forwarded to Yahoo Finance and FT.com. It is available under 'Analyst Reports' from these websites, from multiple professional platforms including Reuters Knowledge, TheMarkets.com, Thomson Research and Capital IQ or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company.php?tickerr=OXB&cod_co ..

Very good newsbut for SP movementa prosavin deal is the news we all wont>


RNS Number : 8079F
Oxford Biomedica PLC
20 January 2010

?


+---------------------------------------------------+--------------------------+
| For Immediate Release | 20 JANUARY 2010 |
+---------------------------------------------------+--------------------------+


OXFORD BIOMEDICA'S USHSTAT(TM) FOR USHER SYNDROME RECEIVES
EUROPEAN ORPHAN
DRUG DESIGNATION


Oxford, UK - 20 January 2010: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that UshStat, the Company's gene therapy for
the treatment of Usher syndrome 1B, has received orphan designation from the
Committee for Orphan Medicinal Products of the European Medicines Agency.


Usher syndrome 1B is an inherited condition that results in hearing loss and
progressive loss of vision from retinitis pigmentosa. It is caused by
abnormalities in a gene called Myosin VIIA (MYO7A). UshStat is designed to
deliver a corrected version of the MYO7A gene into the cells of the retina using
the Company's LentiVector gene delivery technology. In collaboration with
sanofi-aventis, clinical development is expected to start in 2011.


The European Medicines Agency grants orphan drug designation to products that
may provide a significant advantage over current treatments, if any
exist, for life-threatening or chronically debilitating conditions affecting up
to five in 10,000 people in the European Union. Companies with European orphan
drug designation benefit from incentives, including ten years of marketing
exclusivity and reduced regulatory fees.


Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "We are
delighted to have received orphan designation from the European Medicines
Agency for another of our innovative LentiVector-based candidates targeting
debilitating and progressive ocular diseases. This designation is an important
step towards the start of clinical trials of UshStat for Usher syndrome 1B as
part of our landmark collaboration with sanofi-aventis to develop gene
therapies in the field of ophthalmology."
-Ends-

RNS Number : 8079F
Oxford Biomedica PLC
20 January 2010






For Immediate Release
20 JANUARY 2010





OXFORD BIOMEDICA'S USHSTAT FOR USHER SYNDROME RECEIVES
EUROPEAN ORPHAN DRUG DESIGNATION




Oxford, UK - 20 January 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that UshStat, the Company's gene therapy for the treatment of Usher syndrome 1B, has received orphan designation from the Committee for Orphan Medicinal Products of the European Medicines Agency.




Usher syndrome 1B is an inherited condition that results in hearing loss and progressive loss of vision from retinitis pigmentosa. It is caused by abnormalities in a gene called Myosin VIIA (MYO7A). UshStat is designed to deliver a corrected version of the MYO7A gene into the cells of the retina using the Company's LentiVector gene delivery technology. In collaboration with sanofi-aventis, clinical development is expected to start in 2011.




The European Medicines Agency grants orphan drug designation to products that may provide a significant advantage over current treatments, if any exist, for life-threatening or chronically debilitating conditions affecting up to five in 10,000 people in the European Union. Companies with European orphan drug designation benefit from incentives, including ten years of marketing exclusivity and reduced regulatory fees.




Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "We are delighted to have received orphan designation from the European Medicines Agency for another of our innovative LentiVector-based candidates targeting debilitating and progressive ocular diseases. This designation is an important step towards the start of clinical trials of UshStat for Usher syndrome 1B as part of our landmark collaboration with sanofi-aventis to develop gene therapies in the field of ophthalmology."



-Ends-

Anyone here got a handle on the recent Patent-deal? -

I've read the RNS, 22Jan2010.
- Really, it seems to me OXB is strengthening its grip on profits by emboldening their Patent-holding - and - the US researchers have securred a commercial partner = = = = = yet as I read it, both parties have paid very little; the transaction in Cash being covered by buying Shares (=my interpretation, not in the RNS).
Looks like a smart move.
...A small dilution is worth it; if it avoids opportunistic Patent woes later...
I hold a few, most from about 40p so I'm "waiting".